Y-Intercept (HK)’s Achieve Life Sciences ACHV Stock Holding History

Y-Intercept (HK)’s Portfolio ACHV Stock Details ACHV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-116,409	Closed	-$263K	–	1515
2025 Q2	$263K	Buy	+116,409	New	+$332K	0.01%	1393

Other funds holding ACHV

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Y-Intercept (HK)'s ACHV Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Achieve Life Sciences (ACHV) in Q3 2025, closing a stake of 116,409 shares — an estimated $263K sold.

Y-Intercept (HK) first reported a position in ACHV in Q2 2025 and held it in 1 quarter. The position peaked at $263K in Q2 2025. 66 funds tracked by Wall St. Rank hold ACHV as of Q3 2025.

Y-Intercept (HK) reported no remaining Achieve Life Sciences position as of Q3 2025 after selling out during the quarter.
Y-Intercept (HK) sold 116,409 Achieve Life Sciences shares in Q3 2025, an estimated $263K.
Y-Intercept (HK) first reported a position in Achieve Life Sciences in Q2 2025 and held it in 1 quarter.
Y-Intercept (HK)'s Achieve Life Sciences position peaked at $263K in Q2 2025.
66 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.